Citadel Advisors
AVBP icon

Citadel Advisors’s ArriVent BioPharma AVBP Stock Holding History

Citadel Advisors’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.72M Buy
+161,300
New +$3.64M ﹤0.01% 4850

Other funds holding AVBP

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Citadel Advisors's AVBP Position: Q1 2026 in Review

Citadel Advisors reduced its ArriVent BioPharma (AVBP) stake by 64% in Q1 2026, selling an estimated $6.6M and leaving 166,157 shares worth $3.83M. The position accounts for ﹤0.01% of the portfolio, ranked #4793.

Citadel Advisors first reported a position in AVBP in Q1 2024 and has held it in 4 quarters since. The position peaked at $9.23M in Q4 2025. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

  • Citadel Advisors held 166,157 shares of ArriVent BioPharma worth $3.83M as of Q1 2026.
  • Citadel Advisors sold 292,345 ArriVent BioPharma shares in Q1 2026, an estimated $6.6M.
  • ArriVent BioPharma made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #4793 holding.
  • Citadel Advisors first reported a position in ArriVent BioPharma in Q1 2024 and has held it in 4 quarters since.
  • Citadel Advisors's ArriVent BioPharma position peaked at $9.23M in Q4 2025.
  • 139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.